09 August 2020
Visiongain has launched a new report Metagenomics Market Forecast 2020-2030: Forecasts and Analysis by Technology (Sequencing, Bioinformatics), by Products (Instruments, Software, Consumables), by Application (Infectious Disease Diagnosis, Environmental Remediation, Gut Microbe Characterization, Biotechnology, Biofuel, Agriculture) and Geography, with Profiles of Leading Companies.
According to the report published by Visiongain, the Metagenomics market was valued at approximately USD xx billion in 2019. Metagenomics is a study of microbes that involves the complex microbial communities in their natural living environment. The research explores the molecular structure of the body as a whole, and each of its microbes. It is an important concept which is seen to be interdependent and seen as a family instead of as separate entities by the microbes and the host. During the last five-10 years, Metagenomics has demonstrated a new field of research in which the vast majority of organisms in most environments around the world are explained by non-cultured microbes. The study of metagenomics allows users to discover the tools for the creation of new biotechnological dna, enzymes and chemical compounds. In addition, metagenomic libraries are an essential tool for the development of new enzyme activities that allow genetic monitoring for all potential biotechnological applications. This study explores the roots of microbial ecology and biotechnology and its modern use.
The global market for metagenomics is driven largely by increasing requirements to implement high quality DNA sequencing processes that differ from those conventionally used. In addition, the use of modern techniques in genomics without requiring isolation and laboratory cultivation of single species covers the bulk of metagenomics processes. And as many researchers perform comprehensive research in this area, a steady presence is expected on the global metagenomics sector.
A highly consolidated and narrow selling landscape depicts the global metagenomics market. This is mainly because of the presence of a few players on the market who are responsible for most of the processes. However, the competition can witness significant growth and thus attract large revenues, as the numbers of players are forecast to increase.
Metagenomics Market is witnessing Growth due to factors such as
Metagenomics Has Become A Powerful Weapon To Examine The Microbial Populations
At this early stage of metagenomics, the main focus of work is non-eukaryotic bacteria, although the analysis is expected to cover all biological fields in a timely fashion. Metagenomics has become a powerful weapon to examine the microbial populations independent of their potential for laboratory culture using traditional isolation and has also been able to describe their microbial heterogeneity in the ecosystem since many can not yet been cultured. Metagenomics has become a strong weapon for science. This refers to the extraction of DNA from a community to bring together all of the organisms ' genomes in the community. Metagenomics is also described as environmental and community genomics which involves genomic microorganisms analysis through direct extraction and cloning of DNA from a microorganism assembly in the majority of earth environments, such as water or soil. Generic genomes are isolated from the environment, fragmented, and subsequently cloned into an organism using their replicable plasmid. Organisms are then cultivated for metagenomic libraries and analyzes are then performed on the basis of DNA.
The Approach to The Large Demand For New Enzymes And Biocatalysts Has Proven To Be Strong In Metagenomics
Metagenomics has proved to be a fast growing weapons in the microbial world and changed the way microbiologists face many challenges. Metagenomics, the genomic analysis of a microorganism population, has proven to be a powerful central element of the methods aimed at gaining access to the physiology and genetics of uncropped organizationsHigher 1% of the microorganisms in the natural environment can be grown in the laboratory. It was calculated. Incrodible microbes with chemical, biological and functional activities are becoming increasingly known to contain a large amount of natural products for potential use in various industrial and biomedical applications. For the development of new genes, proteins, organic products, bioactive compounds and bioprocesses that have a significant effect in industrial and biotechnological applications, Metagenomics provides an infinite tool.
The approach to the large demand for new enzymes and biocatalysts has proven to be strong in metagenomics. Metagenomics have been used to generate cellulases, lipases, xylanases, amylases, proteases and many other industrial enzymes. Some of the key enzymes released from genetically untapped resources are as follows.
Metagenomics and Medicine
In the latter half of the 20th century, many antibiotics and many other drugs were isolated d from bacteria and show significant change throughout human health. The separation from the microorganism of natural products by the traditional method contributes however to the rediscovery of established antibiotics (97%). The new approach is therefore needed to discover new drugs. Metagenomics can be one of the best origins of new antibiotics.
Shift in Trends
The increasing application of protein screening functional metagenomics is expected to lead to the growth of the segment. For antibiotic resistance and development of vitamins this test is important. In fact, function-driven engineering makes it possible to classify proteins that are active in pollutant degradation and prediction of decline levels. It was used, for example, to understand the organophosphorus compound in situ biodegradation mechanism and to predict its potential to degrade it.
Due to the increased adoption of this software, the sequencing-driven category was the biggest revenue share on the metagenomics industry in 2019. The largest use of this innovation can be attributed to the emergence of new technologies related to bioinformatics, which simplifies workflows and produces fast results. It is able to produce rapid results using bioinformatics tools and computational analyzes such as CoMet, MEGAN, METAREP, CAMERA and IMG / M. In addition, the sequence-based methodology section is supposed to be driven by efforts to maintain a standard repository and to increase the number of metagenomes deposited on information repositories.
In environmental applications, metagenomics have been widely adopted. The section has been motivated by the potential to monitor unaccutaneous microbes, along with a growing interest among microbiologists in serious microbes. Sustainable applications in agriculture include plant development assistance, bioremediation by wastewater treatment, the cleaning of oil spills and leakage of gasoline and the creation of microbial power by biofuel.
Increasing numerous studies to establish a link between microbes and human diseases led to the development of advanced sequencing technologies. The Metagenomic Survey of the bowel microbiota has been augmented by experimental programs such as the American Human Microbiome Project and the European MetaHit Project utilizing comparative gene catalogs. This in essence encourages the development of the sector in human health. The segment is also expected to benefit from increased investment in similar human microbiome studies.
Regional Market Analysis
In 2019, North America dominated the sales market. The presence of many leading biotechnology companies, most of which are focused on the development of metagenomic workflows, can be attributed to this. In May 2015, for example, in the Illumina BaseSpace Apps for use with NGS platforms, CosmosID launched its GENIUS Metagenomics application.
Due to the constant advances to improve bioinformatics technology and genomics in countries like India and China, Asia-Pacific is expected to experience the most rapid economic growth in the projected timeframe. Significant variations in climate and environment across Asian countries is expected to positively influence the adoption of these methods in future.
Competition in the global market
The business segment Agilent CrossLab provides consumer and service supplies. The organization offers a range of chemical and service delivery services that can link the whole laboratory. The diagnosis and genomics section is covered in five business areas that provide solutions including instruments, reagents, consumer products and software that enable customers in the fields of cellular and molecular research to question samples. Illumina offers also a variety of CLIA-certified, CAP-accredited laboratory sequencing, genotyping and NIPT services. Illumina offers various service including Human Whole-Genome Sequencing (WGS) Services, Microarray Services, Certified Service Provider Program (CSPro), Instrument Services, Training and Consulting, and Other Services.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.